Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the most common primary malignancy of bone in children, adolescents, and adults. Despite extensive surgery and adjuvant aggressive high-dose systemic chemotherapy with potentially severe bystander side effects, cure is attainable in about 70% of patients with localized disease and only 20%–30% of those patients with metastatic disease. Targeted therapies clearly are warranted in improving our treatment of this adolescent killer. However, a lack of osteosarcoma-associated/specific markers has hindered development of targeted therapeutics. We describe a novel osteosarcoma-associated cell surface antigen, ALCAM. We, then, create an engineered anti-ALCAM-hybrid polymerized liposomal nanoparticle immunoconjugate (α-AL-HPLN) to specifically target osteosarcoma cells and deliver a cytotoxic chemotherapeutic agent, doxorubicin. We have demonstrated thatα-AL-HPLNs have significantly enhanced cytotoxicity over untargeted HPLNs and over a conventional liposomal doxorubicin formulation. In this way,α-AL-HPLNs are a promising new strategy to specifically deliver cytotoxic agents in osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study demonstrated that ALCAM was associated with tumorigenesis in osteosarcoma [111].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [111]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647 · cited 1×
“Finally from a potential therapeutic delivery perspective, it is best when candidate tumor markers are internalized when bound by ligands or proteins at the cell surface [8].”
BackgroundLipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069 · cited 1×
“Liposomes, unilamellar vesicles composed of natural and/or synthetic lipids, have been a particularly intensively studied system [5].”
BackgroundHaran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934 · cited 1×
“Using this formulation, HPLNs were fabricated and their ability to be actively loaded with doxorubicin through generation of an ion gradient was assessed [21].”
MethodDetection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., & Li, K. C. P. (1998) · Nature Medicine · doi:10.1038/nm0598-623 · Cited by 850 · cited 1×
“The use of diacetylene containing lipids to create polymerizable films and vesicles has been intensively studied for creating biosensors [25] and have been explored as cancer diagnostic and delivery vehicles [26].”
BackgroundAndresen, T. L., Jensen, S. S., & Jørgensen, K. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.12.001 · Cited by 580 · cited 1×
“This latter attribute has been particularly difficult to program into standard liposome formulations [6, 7].”
BackgroundSwart, G. W. M. (2002) · European Journal of Cell Biology · doi:10.1078/0171-9335-00256 · Cited by 251 · cited 1×
“This glycoprotein is a member of the immunoglobulin superfamily and is thought to mediate important cell-cell interactions involved in cell migration, neurogenesis, hematopoiesis, and the immune response [9].”
BackgroundOsteosarcoma of bone and its important recognizable varieties
Dahlin, D. C., & Unni, K. K. (1977) · The American Journal of Surgical Pathology · doi:10.1097/00000478-197701010-00007 · Cited by 234 · cited 1×
“This suggested that at the time of their initial diagnosis clinically undetectable tumor had already spread to distant sites in most patients and that effective systemic anticancer therapy was needed [2].”
BackgroundSequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
Janeway, K. A., & Grier, H. E. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70062-0 · Cited by 234 · cited 1×
“It is also now appreciated that exposure of pediatric cancer patients to cytotoxic chemotherapy can lead to secondary malignancies and other medical maladies, decades after their tumor has been eradicated [4].”
BackgroundIshida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S., & Allen, T. M. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00409-6 · Cited by 216 · cited 1×
“The roughly 50-fold difference in IC50 between free doxorubicin and conventional liposomal doxorubicin seen in our osteosarcoma cell lines is consistent with that found in previously published model systems [22].”
Resultvan Kempen, L. C. L. T., van den Oord, J. J., van Muijen, G. N. P., Weidle, U. H., Bloemers, H. P. J., & Swart, G. W. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64943-7 · Cited by 204 · cited 1×
“For example, an increase in ALCAM expression is found in higher-stage more aggressive malignant melanoma [24].”
Background
Research works printed but not linked: 2
- Huvos AG Bone Tumors: Diagnosis, Treatment, and Prognosis 1991 Philadelphia, Pa, USA WB Saunders
- Gurney JG Swensen AR Bulterys M Malignant bone tumors Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995 1999 Bethesda, Md, USA SEER program, National Cancer Institute 99 110
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“The study demonstrated that ALCAM was associated with tumorigenesis in osteosarcoma [111].”
BackgroundNanotechnology in the targeted drug delivery for bone diseases and bone regeneration
Gu, Wu, Chen, & Xiao, Y. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s44393 · Cited by 212
“nanoparticles, and over a conventional liposomal DXR formulation.(45) Besides, magnetic arsenic trioxide NPs were”
Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications
Madni, A., Sarfraz, M., Rehman, M., Ahmad, M., Akhtar, N., Ahmad, S., Tahir, N., Ijaz, S., Al-Kassas, R., & Löbenberg, R. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3cp55 · Cited by 176
“These polymerized liposomes are completely stable, provide modified release and enhance the half-life of therapeutic agents (186-188).”
BackgroundTargeting nanoparticles for diagnosis and therapy of bone tumors: Opportunities and challenges
Gao, X., Li, L., Cai, X., Huang, Q., Xiao, J., & Cheng, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120404 · Cited by 180
Li, S., Zhang, T., Xu, W., Ding, J., Yin, F., Xu, J., Sun, W. Y., Wang, H., Sun, M., Cai, Z., et al. (2018) · Theranostics · doi:10.7150/thno.18299 · Cited by 157
“For example, activated leukocyte cell adhesion molecule (ALCAM) was thought to be a biomarker of osteosarcoma, and the DOX-loaded anti-ALCAM diabody hybrid polymer liposomal nanoparticle (α-ALCAM-HPLN/DOX) offered more toxicity toward osteosarcoma cells than the non-targeted HPLN/DOX [34].”
Background
Metadata
- Authors
- Federman, N., Chan, J., Nagy, J. O., Landaw, E. M., McCabe, K., Wu, A. M., Triche, T., Kang, H., Liu, B., Marks, J. D., & Denny, C. T.
- Affiliations
- Mattel Children's Hospital (US)
- NanoValent Pharmaceuticals Inc., Bozeman, MT 59718-4012, USA
- University of California, Los Angeles (US)
- University of Southern California (US)
- Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA
- University of California, San Francisco (US)
- Corresponding author
- Federman, Noah
- Venue
- Sarcoma
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-11
- ISSN
- 1357-714X (ISSN-L)
- 1369-1643
- PMC
- PMC3447386
- OpenAlex
- W4213018315
- Cited by
- 44
- References
- 30
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 5
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Sarcoma (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (U54 CA19367, P50 CA092131, P30 CA016042, IIP-1143342)
- National Science Foundation (U54 CA19367, P50 CA092131, P30 CA016042, IIP-1143342)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- osteosarcoma, ALCAM, ALDH1, cell surface receptors, liposomal doxorubicin, targeted drug delivery, immunoconjugates, cytotoxicity, tumor growth inhibition, bone cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.